An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) will participate in fireside chats at three investor conferences in November 2023. Live webcasts will be available on the company's website.
Positive
None.
Negative
None.
WALTHAM, Mass.--(BUSINESS WIRE)--
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:
Jefferies London Healthcare Conference on Tuesday, November 14, 2023 at 11:00 AM ET / 4:00 PM GMT in London, United Kingdom
Stifel Healthcare Conference on Wednesday, November 15, 2023 at 1:50 PM ET in New York, NY
Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 12:00 PM ET in New York, NY
Live webcasts will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. All webcast replays will be archived on the Company’s website for 90 days following the presentation.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
What is the ticker symbol for Deciphera Pharmaceuticals, Inc.?
The ticker symbol for Deciphera Pharmaceuticals, Inc. is DCPH.
Where can I watch the webcasts of the investor conferences?
The live webcasts will be available on the 'Events and Presentations' page in the 'Investors' section of the Company’s website at https://investors.deciphera.com/events-presentations.
How long will the webcast replays be available?
All webcast replays will be archived on the Company’s website for 90 days following the presentation.
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.